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A B ST R AC T 
 
 
The current treatment of Attention Deficit Disorder and Attention 
Deficit with Hyperactivity consists mainly in the administration of 
Straterra (Atomoxetine) Concerta and Ritalin (Methylphenidate). The 
FDA warned that the products might increase systolic, diastolic blood 
pressure, and lead to ventricular arrhythmias. Arrhythmic events and 
sudden cardiac death were described in adults with preexistent heart 
disease.  However, studies on children have failed to demonstrate a clear 
association between the arrhythmic events and these drugs, as 
demonstrated in adults. What should the attitude of the pediatric 
psychiatrist be towards the administration of these products? What 
examination should be made by the psychiatrist before referring the child 
to a pediatric cardiologist? Which patients need a cardiology 
consultation before the administration of these products? What is the 
follow-up after drug initiation? These are some questions that this paper 
aims to answer.   
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Attention deficit, with or without hyperactivity is a 
common condition during childhood, affecting 5% of the 
children [1,2]. This condition poses problems regarding the 
child’s adaptation to social life and educational activity 
during kindergarten, school or high-school.  The most 
effective drugs in the treatment of these conditions are 
psychostimulants such as methylphenidate and non-
stimulants: Atomoxetine [3,4], two drugs that have a 
phenyl-piperidine and phenyl-propane structure (Figure 1). 
Methylphenidate induces the release of norepinephrine and 
dopamine at the synaptic level and stimulates postsynaptic 
receptors (Figure 2), and Atomoxetine is a selective 
inhibitor of norepinephrine re-uptake (Figure 3). Increased 
plasma catecholamines will increase cardiac inotropism 
and heart rate through a beta-1 adrenergic effect and 
increase blood pressure through an alpha-adrenergic effect. 
In 2006, the FDA issued a major warning on 
psychostimulants that they can increase blood pressure and 
drew attention to other cardiac side effects such as 
ventricular arrhythmias and sudden cardiac death. For 
these reasons, the contraindication of psychostimulants has 
been formulated in children with known arrhythmias or 
known heart diseases such as congenital heart diseases, 
acquired myocarditis, dilated or hypertrophic 
cardiomyopathy. However, serious studies published in the 
New England Journal of Medicine [5] and the Journal of 
the American Medical Association [6] have shown that 
these psychostimulants do not increase blood pressure nor 
the risk of ventricular arrhythmias. According to these 
studies, which show the opposite of those formulated by 
the FDA, clinical guidelines developed by psychiatrists 
decided to perform a clinical screening of each child before 
the administration of the psychostimulant. In case of any 
clinical suspicion of known cardiac disease, the child 
should be referred to a cardiologist for an ECG and 
additional cardiac examinations. In a recent paper, David 
et al. [7] investigated the efficacy of a combined treatment: 
cognitive-behavioral therapy + Atomoxetine vs. 
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psychotherapy vs. Atomoxetine for children with 
Attention-Deficit/Hyperactivity Disorder (ADHD). They 
found that the combined treatment was superior to 
medication alone on ADHD symptoms. 
 
Figure 2. The mechanism of action for Atomoxetine 
Figure 3. The mechanism of action for Methylphenidate   
Discussions 
Cardiac arrhythmias in children with Attention Deficit 
who have not received any medication 
Polanczyk et al. have shown that the parasympathetic 
nervous system is not fully developed in children with 
attention deficit and hyperactivity, which translates into 
lower parasympathetic tone [8]. This may be responsible 
for a higher plasma concentration of adrenaline and 
norepinephrine, a higher excretion of catecholamines, as 
demonstrated by Dvorakova et al. [9] by measuring urinary 
catecholamines, increased heart rate, sinus tachycardia, 
and atrial or ventricular premature contractions. This 
explains why some children with attention deficit may also 
suffer from arrhythmias before the beginning of the 
treatment with Methylphenidate or Atomoxetine. This 
mechanism also explains the beneficial effect of the 
administration of beta-blockers when the treatment with 
Atomoxetine or Methylphenidate induces atrial or 
ventricular premature contractions, so that the 
psychostimulant treatment can be continued safely.  
Considering that the two drugs can increase the 
endogenous concentration of catecholamines, we can 
explain the arrhythmic effects by a beta-1 adrenergic effect 
which increases inotropism and also the heart rate. 
Prasad et al.  [10] evaluated 5,289 children with 
attention deficit hyperactivity disorder with the aim of 
identifying arrhythmias that would contraindicate the 
administration of Atomoxetine or Methylphenidate. None 
of all these children suffered from ECG arrhythmias, so 
none of them had any contraindication in the 
administration of psychostimulants. 
Arrhythmic side effects of Methylphenidate and 
Atomoxetine 
The first mention of the arrhythmic side effects of 
Methylphenidate dates back to 2012, when Schellman et al. 




Figure 1. The chemical structure of (A) Methylphenidate 
and (B) Atomoxetine  
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arrhythmias and sudden cardiac death in the adults treated 
with Methylphenidate. Although the study was performed 
on a large number of individuals, it was non-randomized 
and the group in which ventricular arrhythmias were 
recorded had the peculiarity that it included many patients 
with pre-existing cardiac impairments. One year earlier, in 
a large-scale retrospective study including 150,000 
individuals, Habel et al. [12] revealed that neither 
Methylphenidate nor Atomoxetine increases the risk of 
ventricular arrhythmias or the risk of sudden cardiac death. 
It is worth mentioning that the two above-mentioned 
studies were conducted on the adult population and not on 
children. 
Two other large studies by the same author, one on 
21,000 patients receiving Atomoxetine [13] and another on 
44,000 patients receiving Methylphenidate [14], did not 
reveal an increased risk of ventricular arrhythmias or 
sudden cardiac death after drug administration.  
Arj et al. administered Methylphenidate to 141 children 
with attention deficit and hyperactivity disorder and found 
no ECG changes in arrhythmias or significantly increased 
blood pressure levels in these children. 
Tanidir et al. [15] administered Atomoxetine to 41 
children and monitored them by means of ECG and Holter 
ECG. None of these children developed significant 
arrhythmias during the follow-up period. 
In an experimental study, Scherer et al. [16] showed 
that Atomoxetine has the ability to block hERG channels. 
This study could not specify whether the blockage of 
hERG channels has clinical implications, as it was a study 
performed on renal embryonic cells. There are, however, 
reports on the prolongation of the QT interval by 
Atomoxetine with torsade de pointes in which this drug 
was incriminated, but obviously the value of these 
publications is small compared to studies performed on 
larger populations. Studies that have been performed on 
adults show that the short- or long-term administration of 
Methylphenidate or Atomoxetine does not increase the risk 
of QT prolongation [17-19].  
The administration of Methylphenidate and 
Atomoxetine to Children with Cardiac Arrhythmias 
Buchhorn et al. examined 100 children with Attention 
Deficit with and without Hyperactivity, not treated with 
drugs. Of these 100 cases, arrhythmias were observed in 9 
children: 9 had premature atrial contractions, 4 had 
premature ventricular contractions and periods of 
accelerated idioventricular rhythm. Accelerated 
idioventricular rhythm is considered “physiological 
arrhythmia” in children and does not require treatment. Six 
of these children with arrhythmia received 
Methylphenidate and none experienced worsening of the 
clinical arrhythmia, therefore Methylphenidate could be 
continued for a long period of time. 
There are also studies that evaluated the QT interval in 
children receiving Atomoxetine. It is worth mentioning 
that QT measurement differs from one cardiologist to 
another, the best overlapping values being found in 
arrhythmologists [20]. Thus, if QT interval measurements 
are made by different cardiologists, different values are 
obtained. This is the reason why 8.6% of the children who 
were administered the placebo drug had increased QT 
intervals of 30 ms in the meta-analysis by Wernicke et al 
[21].  
Another problem with studies reporting medication-
related arrhythmias is that they do not specify the type of 
arrhythmias: benign arrhythmias such as sinus tachycardia, 
premature atrial or ventricular contractions, QT 
prolongation, or malignant arrhythmias such as ventricular 
tachycardia and ventricular fibrillation [22,23]. The 
differentiation is important because the risk of sudden 
death differs depending on the type of arrhythmia. The 
study by Shin et al. [24] revealed a relatively increased risk 
of arrhythmias 1.6:1 in methylphenidate users compared to 
non-users. It is worth mentioning that there is no reference 
to the type of arrhythmia revealed during follow-up. This 
is a major drawback of a large study with 1,224 patients 
suffering from Attention Deficit and Hyperactivity.  
Anamnestic screening for heart disease 
This screening can be performed by a psychiatrist and 
it requires 3 important questions from the Anamnesis: 1) 
Does the child have a family history of sudden cardiac 
death? 2) Has the child ever been hospitalized for cardiac 
problems or has he undergone heart surgery? and 3) Has 
the child ever had palpitations with an increased heart 
rate > 180/ min or Syncope? This third question "opens the 
door" to other symptoms that can be reported by the patient 
such as palpitations that suggest premature beats, without 
an increased rate > 180/ min. The reason for this last 
question is to eliminate sinus tachycardia that is 
“physiological arrhythmia” and does not require any 
special attention. 
If during Anamnesis, the psychiatrist receives any 
positive answer (YES) to any of the 3 questions, a cardiac 
consultation should be taken into account. This includes a 
clinical examination, an ECG and blood pressure 
measurement. During the physical examination, the 
cardiologist searches for signs of heart failure: edema, 
hepatomegaly, jugular distension, which may be signs of 
underlying heart disease. The presence of a heart murmur 
"per se" does not contraindicate the administration of 
Atomoxetine or Methylphenidate, but the cardiologist 
should differentiate between “physiological murmur” and 
the murmur caused by an underlying heart disease. A blood 
pressure level over 120/70 mmHg before the onset of the 
treatment involves regular measurement of the blood 
pressure during the treatment, at 1 week initially, then at 1-
month follow-up. If the ECG examination does not reveal 
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arrhythmias or prolonged QT interval, the treatment with 
Methylphenidate or Atomoxetine may be initiated. If 
arrhythmias are present on the initial ECG, treatment can 
be started, but it requires reassessment after 1 week and 1 
month.  
The reassessment estimates arrhythmia follow-up:  is 
there any aggravation which requires the interruption of the 
treatment or is the arrhythmia stable and the treatment can 
be maintained? The presence of ventricular arrhythmia 
such as extrasystoles, bigeminies, couplets are not an 
absolute contraindication to Methylphenidate and 
Atomoxetine, but instead, the beta-blocker treatment 
should be initiated with re-assessment at 1 week and 1 
month (Figure 4). 
 
 
Figure 4. Algorithm for screening before the beginning of the treatment with Concerta or Straterra 
Conclusions 
To sum up, the risk of arrhythmic events due to 
Methylphenidate and Atomoxetine is extrapolated to 
children from studies performed on adults. Indeed, 
arrhythmic events were described in adults, some of them 
being fatal, especially if a pre-existing heart disease such 
as myocardial infarction, chronic pulmonary heart disease, 
were present. But these cardiac diseases are not found 
among children.  
Studies on children have not revealed a clearly 
increased arrhythmic risk associated with these drugs. 
However, caution is required in the case of children who 
are known to have congenital heart disease or 
arrhythmogenic cardiomyopathies, and in such cases, a 
cardiac examination should be requested and medication 
should be administered under close ECG monitoring.  
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